Laurie S A, Kris M G
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA.
Clin Lung Cancer. 2000 Apr;1 Suppl 1:S5-9. doi: 10.3816/clc.2000.s.001.
Chemotherapy in recurrent or metastatic non small-cell lung cancer (NSCLC) has been shown to im-prove quality of life, and to provide a modest prolongation of survival. Docetaxel is a semisynthetic taxane that is an active agent for the treatment of NSCLC, both in previously untreated patients as well as those who have relapsed or progressed following cisplatin-based chemotherapy. After encouraging results in phase II studies, randomized trials have shown that treatment with single-agent docetaxel is superior to best supportive care for advanced NSCLC in both untreated and previously treated patients. This article will review the published data on the use of single-agent docetaxel in the treatment of advanced NSCLC.
复发性或转移性非小细胞肺癌（NSCLC）的化疗已被证明可改善生活质量，并适度延长生存期。多西他赛是一种半合成紫杉烷，是治疗NSCLC的一种活性药物，可用于既往未接受过治疗的患者以及那些在以顺铂为基础的化疗后复发或进展的患者。在II期研究取得令人鼓舞的结果后，随机试验表明，对于晚期NSCLC，单药多西他赛治疗在未治疗和既往接受过治疗的患者中均优于最佳支持治疗。本文将综述关于单药多西他赛治疗晚期NSCLC的已发表数据。
